While Viridian Therapeutics Inc has overperformed by 2.86%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VRDN rose by 63.28%, with highs and lows ranging from $32.54 to $9.90, whereas the simple moving average jumped by 74.39% in the last 200 days.
On December 03, 2025, William Blair started tracking Viridian Therapeutics Inc (NASDAQ: VRDN) recommending Outperform. A report published by Truist on November 24, 2025, Initiated its previous ‘Buy’ rating for VRDN. Jefferies also rated VRDN shares as ‘Buy’, setting a target price of $44 on the company’s shares in an initiating report dated August 25, 2025. Wells Fargo December 19, 2024d the rating to Equal Weight on December 19, 2024, and set its price target from $37 to $27. TD Cowen initiated its ‘Buy’ rating for VRDN, as published in its report on November 25, 2024. Needham’s report from September 11, 2024 suggests a price prediction of $38 for VRDN shares, giving the stock a ‘Buy’ rating. Wolfe Research also rated the stock as ‘Outperform’.
Analysis of Viridian Therapeutics Inc (VRDN)
Further, the quarter-over-quarter increase in sales is 81958.14%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Viridian Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -47.40% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 11.28, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.35M can be a very valuable indicator of volatility for VRDN stock. On a monthly basis, the volatility of the stock is set at 4.63%, whereas on a weekly basis, it is put at 3.23%, with a loss of -0.35% over the past seven days. Furthermore, long-term investors anticipate a median target price of $41.12, showing growth from the present price of $31.3, which can serve as yet another indication of whether VRDN is worth investing in or should be passed over.
How Do You Analyze Viridian Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 9.93%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 89.96% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
